Healthcare
Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient formulations provide the essential environment for growing and maintaining cells used in biopharmaceutical manufacturing, vaccine production, regenerative medicine, and advanced biomedical research.
About this update from Avantor, Inc.
LONDON, July 8, 2026 /PRNewswire/ -- Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient formulations provide the essential environment for growing and maintaining cells used in biopharmaceutical manufacturing, vaccine production, regenerative medicine, and advanced biomedical research. The global cell culture media market is growing rapidly, expected to be valued at around US$5.3 billion in 2026 and projected to reach US$12.9 billion by 2033, with a CAGR of 13.6% during the forecast period. This expansion is driven by increasing biologics manufacturing, rapid commercialization of cell and gene therapies, and growing adoption of serum-free and chemically defined production systems. Cell culture media serve as the foundation of modern bioprocessing, supporting the production of monoclonal antibodies, vaccines, recombinant proteins, and regenerative therapies. Rising Biopharmaceutical Production Capacity The rapid expansion of global biopharmaceutical manufacturing is creating sustained demand for advanced cell culture media. Pharmaceutical companies continue investing in large-scale biologics production facilities to meet rising demand for monoclonal antibodies, biosimilars, vaccines, and recombinant proteins. Cell culture media play a critical role by supplying the nutrients required for high-density mammalian cell cultivation throughout commercial manufacturing processes. Multiple biologics manufacturing facilities announced capacity expansions to support growing therapeutic pipelines, while regulatory agencies strengthened guidance supporting advanced biologics and cell therapy manufacturing. Manufacturers increasingly prefer chemically defined and serum-free media because they deliver greater batch consistency, reduce contamination risks, and simplify regulatory compliance. These formulations also improve production efficiency by supporting higher cell densities and predictable manufacturing performance. Beyond commercial biologics, regenerative medicine and personalized therapies continue creating new demand for specialized media formulations. Cell and gene therapy developers require highly optimized nutrient systems capable of supporting complex cell expansion protocols while maintaining product quality. North America remains the largest manufacturing...